TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2	TT11 Sensitive: C2 – Inclusion Criteria TT11 Sensitive : C2
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3	TT11 Sensitive: C3 – Early Trials TT11 Sensitive : C3
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD30-targeted CAR-T immunotherapy Sensitive : C3	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD30-targeted CAR-T immunotherapy Sensitive : C3
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	CART-30 Resistant: C4 – Case Studies CART-30 Resistant : C4	CART-30 Resistant: C4 – Case Studies CART-30 Resistant : C4

CD30-targeted CAR-T immunotherapy

Associations(4)